Ramon Salazar, Jaume Capdevila, Berta Laquente, Jose Luis Manzano, Carles Pericay, Mercedes Martínez Villacampa, Carlos López, Ferran Losa, Maria Jose Safont, Auxiliadora Gómez, Vicente Alonso, Pilar Escudero, Javier Gallego, Javier Sastre, Cristina Grávalos, Sebastiano Biondo, Amalia Palacios, Enrique Aranda
BACKGROUND: Perioperatory chemoradiotherapy (CRT) improves local control and survival in patients with locally advanced rectal cancer (LARC). The objective of the current study was to evaluate the addition of bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC, and to explore biomarkers for downstaging. METHODS: Patients (pts) were randomized to receive 5 weeks of radiotherapy 45 Gy/25 fractions with concurrent CAP 825 mg/m(2) twice daily 5 days per week and BEV 5 mg/kg once every 2 weeks (3 doses) (arm A), or the same schedule without BEV (arm B)...
February 26, 2015: BMC Cancer